Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ArriVent BioPharma, Inc. ( (AVBP) ) just unveiled an update.
On July 21, 2025, ArriVent BioPharma announced the projected release of topline data from its pivotal Phase 3 FURVENT trial for firmonertinib in early 2026. The trial focuses on patients with first-line non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The study, which completed enrollment in Q1 2025, aims to evaluate the safety and efficacy of firmonertinib compared to standard chemotherapy. Firmonertinib has received FDA Breakthrough Therapy and Orphan Drug Designations, highlighting its potential impact on treating NSCLC with uncommon EGFR mutations.
The most recent analyst rating on (AVBP) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on ArriVent BioPharma, Inc. stock, see the AVBP Stock Forecast page.
Spark’s Take on AVBP Stock
According to Spark, TipRanks’ AI Analyst, AVBP is a Underperform.
The overall score reflects the high-risk, high-reward nature of an early-stage biotechnology company like ArriVent BioPharma. While the company shows strong balance sheet stability and strategic pipeline expansion, the lack of current revenue, negative cash flows, and recent downward price trends weigh heavily on the score. Investors should consider the potential long-term benefits of the oncology pipeline expansion balanced against the typical risks associated with biotech investments.
To see Spark’s full report on AVBP stock, click here.
More about ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to address unmet medical needs in cancer treatment. The company aims to leverage its expertise in drug development to advance its lead candidate, firmonertinib, and other novel therapeutics, including next-generation antibody drug conjugates.
Average Trading Volume: 325,990
Technical Sentiment Signal: Sell
Current Market Cap: $809.1M
For detailed information about AVBP stock, go to TipRanks’ Stock Analysis page.